Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Dull

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Vaccine|May 22, 2012
Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal diseasePeter M Dull, E David McIntosh
Vaccine|July 22, 2009
Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all agesMichael Bröker, Peter M Dull, Rino Rappuoli, et al.
Drugs|December 17, 2013
A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development programMiguel O'Ryan, Jeffrey Stoddard, Daniela Toneatto, et al.
Vaccine|July 5, 2015
Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old childrenTimo Vesikari, Roman Prymula, Elizabeth Merrall, et al.
Clinical and Vaccine Immunology : CVI|October 9, 2009
Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, MenactraKeith S Reisinger, Roger Baxter, Stanley L Block, et al.
The Pediatric Infectious Disease Journal|November 2, 2012
Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescentsRobert M Jacobson, Lisa A Jackson, Keith Reisinger, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 2, 2014
Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlersMiguel Tregnaghi, Pio Lopez, Daniel Stamboulian, et al.
Vaccine|January 23, 2026
The role of HPV single-dose vaccination in expanding access in GAVI-supported countries during a period of supply constraintsRobyn Stuart, Nicolas Theopold, Naomi Miall, et al.
Clinical and Vaccine Immunology : CVI|February 19, 2010
Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adultsRoberto Gasparini, Michele Conversano, Gianni Bona, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 30, 2009
Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescentsLisa A Jackson, Roger Baxter, Keith Reisinger, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Vaccine|May 22, 2012
Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal diseasePeter M Dull, E David McIntosh
Vaccine|July 22, 2009
Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all agesMichael Bröker, Peter M Dull, Rino Rappuoli, et al.
Drugs|December 17, 2013
A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development programMiguel O'Ryan, Jeffrey Stoddard, Daniela Toneatto, et al.
Vaccine|July 5, 2015
Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old childrenTimo Vesikari, Roman Prymula, Elizabeth Merrall, et al.
Clinical and Vaccine Immunology : CVI|October 9, 2009
Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, MenactraKeith S Reisinger, Roger Baxter, Stanley L Block, et al.
The Pediatric Infectious Disease Journal|November 2, 2012
Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescentsRobert M Jacobson, Lisa A Jackson, Keith Reisinger, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 2, 2014
Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlersMiguel Tregnaghi, Pio Lopez, Daniel Stamboulian, et al.
Vaccine|January 23, 2026
The role of HPV single-dose vaccination in expanding access in GAVI-supported countries during a period of supply constraintsRobyn Stuart, Nicolas Theopold, Naomi Miall, et al.
Clinical and Vaccine Immunology : CVI|February 19, 2010
Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adultsRoberto Gasparini, Michele Conversano, Gianni Bona, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 30, 2009
Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescentsLisa A Jackson, Roger Baxter, Keith Reisinger, et al.
Pageof 5